Ocuphire Pharma Income from Continuous Operations 2010-2024 | IRD
Ocuphire Pharma income from continuous operations from 2010 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
Ocuphire Pharma Annual Income from Continuous Operations (Millions of US $) |
2023 |
$-10 |
2022 |
$18 |
2021 |
$-57 |
2020 |
$-25 |
2019 |
$-6 |
2018 |
$-14 |
2017 |
$-25 |
2016 |
$-9 |
2015 |
$-14 |
2014 |
$-19 |
2013 |
$-9 |
2012 |
$-6 |
2011 |
$-11 |
2010 |
$-14 |
2009 |
$-3 |
Ocuphire Pharma Quarterly Income from Continuous Operations (Millions of US $) |
2024-06-30 |
$-8 |
2024-03-31 |
$-7 |
2023-12-31 |
$-5 |
2023-09-30 |
$6 |
2023-06-30 |
$-5 |
2023-03-31 |
$-6 |
2022-12-31 |
$34 |
2022-09-30 |
$-5 |
2022-06-30 |
$-5 |
2022-03-31 |
$-7 |
2021-12-31 |
$-6 |
2021-09-30 |
$-4 |
2021-06-30 |
$-7 |
2021-03-31 |
$-39 |
2020-12-31 |
$-19 |
2020-09-30 |
$-1 |
2020-06-30 |
$-2 |
2020-03-31 |
$-3 |
2019-12-31 |
$1 |
2019-09-30 |
$-2 |
2019-06-30 |
$-2 |
2019-03-31 |
$-2 |
2018-12-31 |
$-3 |
2018-09-30 |
$-5 |
2018-06-30 |
$-4 |
2018-03-31 |
$-2 |
2017-12-31 |
$-4 |
2017-09-30 |
$-1 |
2017-06-30 |
$1 |
2017-03-31 |
$-22 |
2016-12-31 |
$-1 |
2016-09-30 |
$-3 |
2016-06-30 |
$-2 |
2016-03-31 |
$-4 |
2015-12-31 |
$-3 |
2015-09-30 |
$-4 |
2015-06-30 |
$-3 |
2015-03-31 |
$-4 |
2014-12-31 |
$-2 |
2014-09-30 |
$-2 |
2014-06-30 |
$0 |
2014-03-31 |
$-15 |
2013-12-31 |
$-3 |
2013-09-30 |
$-2 |
2013-06-30 |
$-3 |
2013-03-31 |
$-2 |
2012-12-31 |
$-0 |
2012-09-30 |
$-3 |
2012-06-30 |
$-1 |
2012-03-31 |
$-2 |
2011-12-31 |
$0 |
2011-09-30 |
$-1 |
2011-06-30 |
$-6 |
2011-03-31 |
$-4 |
2010-12-31 |
$-3 |
2010-09-30 |
$0 |
2010-06-30 |
$-4 |
2010-03-31 |
$-8 |
2009-12-31 |
$2 |
2009-09-30 |
$-1 |
2009-06-30 |
$-2 |
2009-03-31 |
$-1 |
Sector |
Industry |
Market Cap |
Revenue |
|
|
$0.000B |
$0.000B |
Ocuphire Pharma Inc. is a clinical-stage ophthalmic biopharmaceutical company. It is focused on developing and commercializing therapies for the treatment of several eye disorders. The company's product pipeline includes Nyxol Eye Drops(R) and APX3330. Ocuphire Pharma Inc., formerly known as Rexahn Pharmaceuticals Inc., is based in FARMINGTON HILLS, Mich.
|